文献速递头颈部肿瘤放疗

rhuGM-CSF漱口液预防头颈癌放疗口腔黏膜炎的随机对照试验

Effects of rhuGM-CSF on prevention and treatment of oral mucositis in patients receiving radiotherapy for head and neck cancer: A randomized controlled trial.
PubMed 文献 · Radiother Oncol · 2026-04-09

本研究纳入100例接受放疗的头颈癌患者,随机分为预防组(放疗起始即用rhuGM-CSF漱口液,n=50)和治疗组(出现1级口腔黏膜炎后才开始用,n=50)。符合方案分析显示,预防组重度口腔黏膜炎(SOM)发生率显著降低(33.3% vs 66.7%;HR=0.31,95%CI 0.17-0.57,p<0.001),中位持续时间更短(0天 vs 14天,p<0.001)。探索性分析提示基线活化CD4+CD38+/CD4+T细胞百分比低于39.97%时,每增加1个单位与SOM风险降低9%相关(HR=0.91,95%CI 0.87-0.95,p<0.001)。

要点

  • 预防性使用rhuGM-CSF漱口液可显著降低头颈癌放疗患者SOM发生率。
  • 预防组SOM中位持续时间为0天,显著短于治疗组的14天。
  • 基线活化CD4+CD38+/CD4+T细胞百分比可能是黏膜脆弱性的预测生物标志物。

核心结论

  • 预防性应用rhuGM-CSF漱口液可显著降低头颈癌放疗患者SOM的发生率和持续时间。
  • 探索性分析提示基线活化CD4+CD38+/CD4+T细胞百分比可能是黏膜脆弱性的潜在预测生物标志物,尚待进一步验证。

研究设计与样本

  • 随机对照试验,纳入100例接受放疗的头颈癌患者。
  • 预防组(n=50)在放疗开始时即开始使用rhuGM-CSF漱口液。
  • 治疗组(n=50)仅在出现1级口腔黏膜炎后才开始使用漱口液。
  • 主要终点为SOM发生率;次要终点包括SOM持续时间、发生时间和生活质量。
  • 进行了探索性免疫生物标志物分析。

主要发现

  • 符合方案分析中,预防组SOM发生率为33.3%,治疗组为66.7%(HR=0.31,95%CI 0.17-0.57,p<0.001)。
  • 预防组SOM中位持续时间为0天,治疗组为14天(p<0.001)。
  • 基线活化CD4+CD38+/CD4+T细胞百分比低于39.97%时,每增加1个单位与SOM风险降低9%相关(HR=0.91,95%CI 0.87-0.95,p<0.001)。

临床怎么用

  • 对于接受放疗的头颈癌患者,可考虑从放疗起始即预防性使用rhuGM-CSF漱口液以降低SOM发生率和缩短持续时间。
  • 基线活化CD4+CD38+/CD4+T细胞百分比可作为探索性指标辅助识别黏膜脆弱患者,但尚需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Severe oral mucositis (SOM) is a serious complication of radiotherapy for head and neck cancer (HNC) with limited prevention options. This study evaluated the efficacy of prophylactic recombinant human granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) mouthwash in reducing SOM incidence and explored correlative immune biomarkers. MATERIALS AND METHODS: In this randomized study, 100 HNC patients undergoing radiotherapy were assigned to a prevention group (n = 50), starting rhuGM-CSF mouthwash at radiotherapy initiation, or a treatment group (n = 50), initiating mouthwash only after onset of grade 1 OM. The primary endpoint was SOM incidence. Secondary endpoints included SOM duration, onset time, and quality of life (QoL). Exploratory immune biomarker analysis was performed. RESULTS: In the per-protocol analysis, the incidence of SOM in patients receiving prophylactic rhuGM-CSF treatment was significantly reduced (33.3% vs. 66.7%; HR = 0.31, 95% CI 0.17-0.57, p < 0.001), and the median duration was shorter (0 vs. 14 days, p < 0.001) compared to the treatment group. Below the 39.97% threshold, each unit increase in baseline percentage of activated CD4 + CD38+ / CD4 + T cells (%) was associated with a 9% reduction in the risk of SOM (HR = 0.91, 95% CI 0.87-0.95, p < 0.001). CONCLUSIONS: The prophylactic application of rhuGM-CSF mouthwash significantly decreases both the incidence and duration of SOM in patients with HNC receiving radiotherapy. An exploratory analysis suggested that the baseline percentage of activated CD4 + CD38+ / CD4 + T cells (%) could be a potential predictive biomarker for mucosal vulnerability and this hypothesis remains to be further verified.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Ye W, Zhang M, Gong M, et al. Effects of rhuGM-CSF on prevention and treatment of oral mucositis in patients receiving radiotherapy for head and neck cancer: A randomized controlled trial. Radiother Oncol. 2026. PMID: 41966279. doi:10.1016/j.radonc.2026.111527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。